Silo Pharma (NASDAQ: SILO) announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the company's common stock. The program, which was disclosed in a press release, allows purchases to be made on the open market, through privately negotiated transactions, or otherwise, in compliance with Securities and Exchange Commission rules and applicable legal requirements. The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations, and the program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at its discretion.
As of November 13, 2025, Silo reported 13,318,273 shares of common stock outstanding, according to its quarterly report for the period ended September 30, 2025. The repurchase program could help support the stock price and signal management's confidence in the company's intrinsic value. For investors, such programs often indicate that the company believes its shares are undervalued.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories, as detailed in the full press release available at https://ibn.fm/gU3uZ.
The authorization of a share repurchase program comes at a time when Silo continues to advance its pipeline. The company's focus on stress-induced psychiatric disorders and chronic pain positions it in high-demand therapeutic areas. However, as a developmental-stage company, Silo faces significant risks, including the need for substantial additional capital to fund research and development. The repurchase program may be seen as a strategic move to enhance shareholder value while the company works toward clinical milestones.
Investors should note that the repurchase program does not guarantee any specific share price or return. The company may suspend or discontinue the program at any time. For ongoing updates on Silo Pharma, the company maintains a newsroom at https://ibn.fm/SILO.
